Currently, the reliance on mitochondrial respiration has been demonstrated in drug-resistant cancer cells and DTP cells from multiple cancer sources.211–215 In BRAF-mutated melanomas, blocking the mitochondrial respiratory chain of slow-cell-cycle JARID1B(high) cells, now referred to as DTP cells, has been proven effective in inhibiting their drug resistant behavior.78 Furthermore, in the field of triple-negative breast cancer treatment research,49 Phase 1 clinical development is underway to investigate the efficacy of an oxidative phosphorylation inhibitor. Here, BRAF is linked to cancer.